Pardes Bio

Pardes Biosciences was a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. Founded in 2020 and based in Carlsbad, California, it used structure-based drug design and a tunable, reversible covalent chemistry platform. Its lead candidate, PBI-0451, was an oral direct-acting antiviral for SARS-CoV-2. The company was acquired in 2023 and no longer operates independently. It has no public API, developer program, or technical integration surface, and its former domain (pardesbio.com) is now a parked/registrar page.

Pardes Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Biopharmaceutical, Pharmaceuticals, and Drug Discovery.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyBiopharmaceuticalPharmaceuticalsDrug DiscoveryAntiviralsLife Sciences

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/pardes-bio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: pardes-bio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/pardes-bio.png
name: Pardes Bio
description: Pardes Biosciences was a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing
  novel therapeutics to treat and prevent viral diseases. Founded in 2020 and based in Carlsbad, California, it used structure-based
  drug design and a tunable, reversible covalent chemistry platform. Its lead candidate, PBI-0451, was an oral direct-acting
  antiviral for SARS-CoV-2. The company was acquired in 2023 and no longer operates independently. It has no public API, developer
  program, or technical integration surface, and its former domain (pardesbio.com) is now a parked/registrar page.
url: https://raw.githubusercontent.com/api-evangelist/pardes-bio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- y-combinator
x-tier: stub
x-tier-reason: portfolio-lead
x-status: defunct
x-status-reason: acquired-2023; former domain pardesbio.com now parked; no API surface
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Pharmaceuticals
- Drug Discovery
- Antivirals
- Life Sciences
apis: []
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io